1
|
Volokhov DV, Furtak V, Allen C, Pulle G, Zajac MD, Levin Y, Kochba E, Moore SM. Robust humoral immune response against rabies virus in rabbits and guinea pigs immunized with plasmid DNA vectors encoding rabies virus glycoproteins - An approach to the production of polyclonal antibody reagents. Mol Cell Probes 2022; 64:101833. [PMID: 35691598 DOI: 10.1016/j.mcp.2022.101833] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/29/2022] [Revised: 06/06/2022] [Accepted: 06/06/2022] [Indexed: 11/28/2022]
Abstract
DNA-based immunization has been previously shown to be an efficient approach to induce robust immunity against infectious diseases in animals and humans. The advantages of DNA vaccines are simplicity of their construction and production, low cost, high stability, and ability to elicit a full spectrum of immune responses to target antigens. The goals of this study were (i) to assess the antibody immune response to rabies virus glycoproteins (rGPs) in rabbits and guinea pigs after intramuscular immunization with pTargeT and pVAC2-mcs mammalian expression vectors encoding either the wild-type (WT) or codon-optimized (cOPT) rGP genes; and (ii) to prepare in-house rabbit anti-rGP polyclonal antibody reagents suitable for in Single Radial Immunodiffusion (SRID) and Indirect Fluorescent Antibody (IFA) assays. The maximum antibody responses against rabies virus in rabbits and guinea pigs were observed after immunization series with 500 μg/dose of pVAC2-mcs vector encoding either the WT or cOPT rGP genes adjuvanted with Emulsigen-D. No significant difference in the anti-rabies virus neutralizing antibody titers was observed in rabbits immunized with the WT and cOPT rGPs. The in-house rabbit anti-rGP polyclonal antibody reagents reacted comparable to the current reference reagents in SRID and IFA assays. The results of the study demonstrated that the DNA immunization of animals with the WT or cOPT rGPs is a promising approach to either induction of high anti-rabies virus neutralizing antibody titers in vivo or for production of polyclonal antibody reagents against rabies.
Collapse
Affiliation(s)
- Dmitriy V Volokhov
- Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, 10903 New Hampshire Ave., Silver Spring, MD, 20993, USA.
| | - Vyacheslav Furtak
- Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, 10903 New Hampshire Ave., Silver Spring, MD, 20993, USA
| | - Cynthia Allen
- Vaccine Quality Division, Center for Biologics Evaluation (CBE), Biologic and Radiopharmaceutical Drugs Directorate (BRDD), Health Canada, 100 Eglantine Driveway, Ottawa, ON K1A 0K9, Canada
| | - Gayle Pulle
- Vaccine Quality Division, Center for Biologics Evaluation (CBE), Biologic and Radiopharmaceutical Drugs Directorate (BRDD), Health Canada, 100 Eglantine Driveway, Ottawa, ON K1A 0K9, Canada
| | - Michelle D Zajac
- Kansas State University, College of Veterinary Medicine, Department of Diagnostic Medicine and Pathobiology, 1800 Denison Ave., Manhattan, KS, 66506, USA
| | - Yotam Levin
- NanoPass Technologies Ltd., 3 Golda Meir St., Nes Ziona, 7403648, Israel
| | - Efrat Kochba
- NanoPass Technologies Ltd., 3 Golda Meir St., Nes Ziona, 7403648, Israel
| | - Susan M Moore
- The University of Missouri Veterinary Medical Diagnostic Laboratory (VMDL), One Health Laboratory, 1509 Rollins St., Columbia, MO, 65211, USA
| |
Collapse
|
2
|
Abstract
Cited are literary data related to the development of DNA vaccines against rabies virus. Research results regarding gene vaccination of different models of laboratory animals and different ways of vaccine introduction are presented. Possibility to potentiate immunogenicity of DNA vaccines using adjuvants and cytokines is considered. Ways of improving of polynucleotide vaccines are discussed.
Collapse
|
3
|
Abstract
Rabies, the most fatal of all infectious diseases, remains a major public health problem in developing countries, claiming the lives of an estimated 55,000 people each year. Most fatal rabies cases, with more than half of them in children, result from dog bites and occur among low-income families in Southeast Asia and Africa. Safe and efficacious vaccines are available to prevent rabies. However, they have to be given repeatedly, three times for pre-exposure vaccination and four to five times for post-exposure prophylaxis (PEP). In cases of severe exposure, a regimen of vaccine combined with a rabies immunoglobulin (RIG) preparation is required. The high incidence of fatal rabies is linked to a lack of knowledge on the appropriate treatment of bite wounds, lack of access to costly PEP, and failure to follow up with repeat immunizations. New, more immunogenic but less costly rabies virus vaccines are needed to reduce the toll of rabies on human lives. A preventative vaccine used for the immunization of children, especially those in high incidence countries, would be expected to lower fatality rates. Such a vaccine would have to be inexpensive, safe, and provide sustained protection, preferably after a single dose. Novel regimens are also needed for PEP to reduce the need for the already scarce and costly RIG and to reduce the number of vaccine doses to one or two. In this review, the pipeline of new rabies vaccines that are in pre-clinical testing is provided and an opinion on those that might be best suited as potential replacements for the currently used vaccines is offered.
Collapse
Affiliation(s)
- Hildegund C. J. Ertl
- The Wistar Institute, Philadelphia, Pennsylvania, United States of America
- * E-mail:
| |
Collapse
|
4
|
Bahloul C, Ahmed SBH, B'chir BI, Kharmachi H, Hayouni EA, Dellagi K. Post-exposure therapy in mice against experimental rabies: a single injection of DNA vaccine is as effective as five injections of cell culture-derived vaccine. Vaccine 2003; 22:177-84. [PMID: 14615144 DOI: 10.1016/s0264-410x(03)00568-1] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
Two rabies post-exposure therapies were comparatively evaluated: BALB/c mice were challenged at day 0 with rabies virus and then received either a single dose of rabies DNA vaccine administered at day 0, or five doses of cell culture-derived rabies vaccine administered at days 0, 3, 7, 15 and 28. Both regimens, rapidly triggered protective levels of neutralizing antibodies against rabies virus in vaccinated mice. In addition, one injection of DNA vaccine protected 53% of the challenged mice, compared to 40% of mice protected after five injections of cell culture-derived vaccine. We conclude that rabies post-exposure vaccination in BALB/c mice, based on a single administration of rabies DNA vaccine might be at least as effective as five injections of cell culture-derived vaccine.
Collapse
Affiliation(s)
- Chokri Bahloul
- Laboratory of Immunology, Vaccinology and Molecular Genetics, Institut Pasteur de Tunis, 13 Place Pasteur BP-74, 1002, Tunis-Belvedere, Tunisia.
| | | | | | | | | | | |
Collapse
|
5
|
Abstract
DNA vaccines have shown efficacy in preclinical animal models in preventing or even treating a variety of diseases caused by infectious agents, malignancies or immunological disorders. One of the main perceived advantages of DNA vaccines for use in less developed countries is their low cost. Nevertheless, in general, immune responses elicited by DNA vaccines are less potent than those induced by traditional vaccines or second generation viral recombinant vaccines, and their efficacy in human Phase I trials has been disappointing. DNA vaccines have shown good efficacy in preventing rabies in some experimental animal models; their performance in postexposure treatment has been less impressive. Considering that rabies is nearly always fatal, efficacious vaccines are available and treatment in most cases is initiated after exposure, the development of current DNA vaccines to rabies for use in humans is, at the current time, not appropriate.
Collapse
|
6
|
Ioannou XP, Griebel P, Hecker R, Babiuk LA, van Drunen Littel-van den Hurk S. The immunogenicity and protective efficacy of bovine herpesvirus 1 glycoprotein D plus Emulsigen are increased by formulation with CpG oligodeoxynucleotides. J Virol 2002; 76:9002-10. [PMID: 12186884 PMCID: PMC136463 DOI: 10.1128/jvi.76.18.9002-9010.2002] [Citation(s) in RCA: 99] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/16/2002] [Accepted: 06/11/2002] [Indexed: 11/20/2022] Open
Abstract
The immunogenicity and protective efficacy of a bovine herpesvirus 1 (BHV-1) subunit vaccine formulated with Emulsigen (Em) and a synthetic oligodeoxynucleotide containing unmethylated CpG dinucleotides (CpG ODN) was determined in cattle. A truncated, secreted version of BHV-1 glycoprotein D (tgD) formulated with Em and CpG ODN at concentrations of 25, 2.5, or 0.25 mg/dose produced a more balanced immune response, higher levels of virus neutralizing antibodies, and greater protection after BHV-1 challenge compared to tgD adjuvanted with either Em or CpG ODN alone. In contrast, tgD formulated with Em and either 25 mg of a non-CpG ODN or another immunostimulatory compound, dimethyl dioctadecyl ammonium bromide, induced similar immunity and protection compared to tgD formulated with Em alone, a finding which confirms the immunostimulatory effect of ODN to be CpG motif mediated. Our results demonstrate the ability of CpG ODN to induce a strong and balanced immune response in a target species.
Collapse
Affiliation(s)
- X P Ioannou
- Veterinary Infectious Disease Organization, Saskatoon, Saskatchewan, S7N 5E3 Canada
| | | | | | | | | |
Collapse
|
7
|
Cohen H, Levy RJ, Gao J, Fishbein I, Kousaev V, Sosnowski S, Slomkowski S, Golomb G. Sustained delivery and expression of DNA encapsulated in polymeric nanoparticles. Gene Ther 2000; 7:1896-905. [PMID: 11127577 DOI: 10.1038/sj.gt.3301318] [Citation(s) in RCA: 277] [Impact Index Per Article: 11.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Sustained release polymeric gene delivery systems offer increased resistance to nuclease degradation, increased amounts of plasmid DNA (pDNA) uptake, and the possibility of control in dosing and sustained duration of pDNA administration. Furthermore, such a system lacks the inherent problems associated with viral vectors. Biodegradable and biocompatible poly(DL-lactide-co-glycolide) polymer was used to enacapsulate pDNA (alkaline phosphatase, AP, a reporter gene) in submicron size particles. Gene expression mediated by the nanoparticles (NP) was evaluated in vitro and in vivo in comparison to cationic-liposome delivery. Nano size range (600 nm) pDNA-loaded in poly(DL-lactide-co-glycolide) polymer particles with high encapsulation efficiency (70%) were formulated, exhibiting sustained release of pDNA of over a month. The entrapped plasmid maintained its structural and functional integrity. In vitro transfection by pDNA-NP resulted in significantly higher expression levels in comparison to naked pDNA. Furthermore, AP levels increased when the transfection time was extended, indicating sustained activity of pDNA. However, gene expression was significantly lower in comparison with standard liposomal transfection. Seven days after i.m. injections in rats, naked pDNA and pDNA-NP were found to be significantly more potent (1-2 orders of magnitude) than liposomal pDNA. Plasmid DNA-NP treatment exhibited increased AP expression after 7 and 28 days indicating sustained activity of the NP.
Collapse
Affiliation(s)
- H Cohen
- Department of Pharmaceutics, School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, Israel
| | | | | | | | | | | | | | | |
Collapse
|
8
|
Corbeil S, Kurath G, LaPatra SE. Fish DNA vaccine against infectious hematopoietic necrosis virus: efficacy of various routes of immunisation. FISH & SHELLFISH IMMUNOLOGY 2000; 10:711-23. [PMID: 11185755 DOI: 10.1006/fsim.2000.0286] [Citation(s) in RCA: 43] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/15/2023]
Abstract
The DNA vaccine, pIHNVw-G, contains the gene for the glycoprotein (G) of the rhabdovirus infectious hematopoietic necrosis virus (IHNV), a major pathogen of salmon and trout. The relative efficacy of various routes of immunisation with pIHNVw-G was evaluated using 1.8 g rainbow trout fry vaccinated via intramuscular injection, scarification of the skin, intraperitoneal injection, intrabuccal administration, cutaneous particle bombardment using a gene gun, or immersion in water containing DNA vaccine-coated beads. Twenty-seven days after vaccination neutralising antibody titres were determined, and 2 days later groups of vaccinated and control unvaccinated fish were subjected to an IHNV immersion challenge. Results of the virus challenge showed that the intramuscular injection and the gene gun immunisation induced protective immunity in fry, while intraperitoneal injection provided partial protection. Neutralising antibodies were not detected in sera of vaccinated fish regardless of the route of immunisation used, suggesting that cell mediated immunity may be at least partially responsible for the observed protection.
Collapse
Affiliation(s)
- S Corbeil
- Department of Pathobiology, University of Washington, Seattle 98195-7238, USA
| | | | | |
Collapse
|
9
|
Petersen TR, Bregenholta S, Pedersen LO, Nissen MH, Claesson MH. Human p53(264-272) HLA-A2 binding peptide is an immunodominant epitope in DNA-immunized HLA-A2 transgenic mice. Cancer Lett 1999; 137:183-91. [PMID: 10374840 DOI: 10.1016/s0304-3835(98)00353-x] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
C57BL/10 mice transgenic for HLA-A2 were immunized with either a full-length DNA-construct of the tumor suppressor p53 or with a minigene encoding the p53-derived immunodominant peptide p53(264)LLGRNSFEV272 (L9V). Vaccination with the full-length p53 construct induced potent cytotoxic activity of splenocytes against L9V-pulsed target cells after in vivo re-stimulation. Vaccination with the L9V-encoding minigene likewise induced specific anti-L9V cytotoxicity in vitro. Subsequent experiments revealed that peptide-pulsed dendritic cells were the most efficient cell types for in vitro re-stimulation. In concordance with this, immunization with L9V-pulsed dendritic cells also induced a potent and specific anti-L9V cytotoxic response in vitro. These data show that HLA-A2/peptide-specific cytotoxic immunity can be generated in vivo against the same immunodominant epitope by immunizing either with full-length DNA or with a DNA minigene encoding the immunodominant peptide epitope.
Collapse
Affiliation(s)
- T R Petersen
- Department of Medical Anatomy, The Panum Institute, University of Copenhagen, Denmark
| | | | | | | | | |
Collapse
|
10
|
Abstract
Although vaccination has had a dramatic impact on reducing economic losses due to infectious diseases, vaccination technology has not changed dramatically over the last 200 years. However, with the advent of biotechnology and our understanding of virulence factors of infectious agents combined with our knowledge of the host immune response, we are now witnessing a revolution in the number of new agents which may potentially be controlled by vaccination, as well as the approaches being used to develop vaccines. These approaches include subunit vaccines, genetically modified live vaccines and most recently, polynucleotide vaccines. Pathogens involved in bovine respiratory disease are used as models to describe recent advances in developing new vaccines that have the potential to be safer, more economical and more efficacious. Emphasis will be placed on identification of specific proteins involved in inducing protective immunity and producing these in a mammalian expression system as subunit vaccines formulated with adjuvants. To increase the duration of immunity, the genes encoding these antigens have been introduced directly into animals as polynucleotide vaccines. The benefits and short-comings, as well as the practical problems associated (both scientific and regulatory) with eventual acceptance of these vaccines, are discussed.
Collapse
Affiliation(s)
- L A Babiuk
- Veterinary Infectious Disease Organization, Sask., Canada.
| |
Collapse
|
11
|
Babiuk LA, Lewis J, van den Hurk S, Braun R. DNA immunization: present and future. ADVANCES IN VETERINARY MEDICINE 1999; 41:163-79. [PMID: 9890016 DOI: 10.1016/s0065-3519(99)80015-9] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Affiliation(s)
- L A Babiuk
- Veterinary Infectious Disease Organization, Saskatoon, Saskatchewan, Canada
| | | | | | | |
Collapse
|
12
|
Interactions between the Immune System and Gene Therapy Vectors: Bidirectional Regulation of Response and Expression**Received for publication September 19, 1997. Adv Immunol 1998. [DOI: 10.1016/s0065-2776(08)60611-2] [Citation(s) in RCA: 44] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
|
13
|
Ambriović A, Adam M, Monteil M, Paulin D, Eloit M. Efficacy of replication-defective adenovirus-vectored vaccines: protection following intramuscular injection is linked to promoter efficiency in muscle representative cells. Virology 1997; 238:327-35. [PMID: 9400605 DOI: 10.1006/viro.1997.8842] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
To investigate the respective role of transduced cells in the induction of immune response following intramuscular inoculation of adenovirus-based vaccines, we generated several replication-defective adenoviruses expressing the glycoprotein D gene of pseudorabies virus under the control of four different promoters: major late promoter of adenovirus type 2, human cytomegalovirus immediate-early promoter/enhancer (CMV), Rous sarcoma virus-long terminal repeat promoter, and human desmin gene 5' regulatory region (DES). All the adenovirus constructs were able to fully protect mice, in the contrary of direct DNA inoculation of plasmids harboring the same transcription units. The far most effective adenovirus constructs, on the criterion of protective doses and specific antibody response induction, were those in which the foreign gene was driven by the DES or CMV promoter. Wide variations in promoter strength in vitro were evidenced in several cell culture types representative of putative target cells following muscular inoculation (myoblasts, myotubes, fibroblasts, macrophages, and endothelial cells). The level of efficacy in vivo, was not correlated with the level of expression in vitro in myotubes, but paralleled the level of expression in endothelial cells and in myoblasts. Together with previously published data, these results suggest that, following adenovirus injection, locally produced cytokines may induce myoblasts to act as local antigen presenting cells.
Collapse
MESH Headings
- Adenoviruses, Human/genetics
- Adenoviruses, Human/physiology
- Animals
- Antibodies, Viral/blood
- Antibodies, Viral/immunology
- Antigens, Viral/biosynthesis
- Antigens, Viral/genetics
- Antigens, Viral/immunology
- Cell Line, Transformed
- Defective Viruses/genetics
- Defective Viruses/physiology
- Genetic Vectors
- Herpesvirus 1, Suid/immunology
- Humans
- Injections, Intramuscular
- Mice
- Muscles/cytology
- Plasmids
- Promoter Regions, Genetic
- Pseudorabies/immunology
- Pseudorabies/prevention & control
- Recombinant Fusion Proteins/biosynthesis
- Recombinant Fusion Proteins/genetics
- Recombinant Fusion Proteins/immunology
- Vaccines, Synthetic/immunology
- Viral Envelope Proteins/biosynthesis
- Viral Envelope Proteins/genetics
- Viral Envelope Proteins/immunology
- Viral Vaccines/immunology
- Virus Replication
Collapse
Affiliation(s)
- A Ambriović
- Unité de Génétique Moléculaire, Génétique virale, INRA, Ecole Nationale Vétérinaire, Maisons Alfort, France
| | | | | | | | | |
Collapse
|
14
|
Abstract
In just a few years, injection of plasmid DNA to elicit immune responses in vivo has developed from an interesting observation to a viable vaccine strategy. DNA vaccines have been shown to elicit both cellular and humoral immune responses and to be effective in a variety of preclinical bacterial, viral, and parasitic animal models. This review will discuss the current knowledge of vector design, methods of plasmid delivery, immune responses elicited by various DNA vaccines, safety issues, and production and release of plasmid as a vaccine product. The potential of this new vaccine strategy and its future prospects is summarized.
Collapse
Affiliation(s)
- D L Montgomery
- Department of Virus and Cell Biology, Merck Research Laboratories, West Point, PA 19486, USA
| | | | | | | |
Collapse
|
15
|
Abstract
Cancer is one of the leading causes of death today, and new therapeutic approaches are continuously being explored. In recent years, cancer vaccines have been tried with the aim of induction of an active specific immune response against the tumor. Although some successful results are obtained, cure rates are still disappointing. The main reason for failure is that vaccines are applied to patients diagnosed with cancer; in these patients, tumor cell burden is so high that it is almost impossible to overcome the disease by increasing the immune response with vaccines at this stage. This hypothesis is based on the following idea: since therapy for cancer is unsuccessful in the majority of patients, methods of prevention should be improved. Immunization against microorganisms has largely prevented morbidity and mortality from infectious disease. In a similar way, if we immunize people before the development of malignant disease with tumor-specific vaccines, then prevention of cancer may be possible.
Collapse
Affiliation(s)
- H Demiroğlu
- Hacettepe University Medical School, Department of Hematology, Ankara, Turkey
| |
Collapse
|
16
|
Abstract
DNA immunization has recently emerged as a highly promising approach for the prevention and therapy of a wide range of infectious and non-infectious diseases. Here, we review the rapid development of this field and recent advances in our understanding of some of the mechanisms by which DNA vaccines stimulate the immune system.
Collapse
Affiliation(s)
- A J Ramsay
- Division of Immunology and Cell Biology, John Curtin School of Medical Research, Australian National University, Canberra, Australia.
| | | | | |
Collapse
|
17
|
Choi AH, Knowlton DR, McNeal MM, Ward RL. Particle bombardment-mediated DNA vaccination with rotavirus VP6 induces high levels of serum rotavirus IgG but fails to protect mice against challenge. Virology 1997; 232:129-38. [PMID: 9185596 DOI: 10.1006/viro.1997.8552] [Citation(s) in RCA: 34] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
The rotavirus inner capsid protein VP6 contains conserved epitopes that are potential targets for eliciting protective immunity against different serotypes within the same group of rotavirus. In order to determine whether VP6 alone can induce protective immunity, an expression vector pcDNA1/EDIM6 containing gene 6 of rotavirus EDIM strain was constructed and used as a vaccine in an adult mouse model. Cloned gene 6 was determined to be 1356 nucleotides long and contained a 5' noncoding region of 23 nucleotides, a 3' noncoding region of 139 nucleotides, and a coding frame of 1194 nucleotides for a polypeptide of 397 amino acid residues. Recombinant VP6 was expressed in rabbit reticulocyte lysate and the heat-denatured recombinant VP6 migrated in SDS-gels with an apparent molecular weight of approximately 43 kDa. Five additional polypeptide bands corresponding to oligomers of recombinant VP6 were observed when the expressed product was not heat denatured. To determine the immunogenicity of recombinant VP6, female BALB/c mice were injected intramuscularly or intradermally with pcDNA1/EDIM6, or were inoculated epidermally with plasmid-coated gold beads using the Geniva Accell particle delivery device. Only intradermal injection and particle delivery elicited measurable serum anti-rotavirus IgG responses, but responses developed following particle delivery were significantly (P < 0.001) greater. However, none of the delivery methods induced serum or stool anti-rotavirus IgA responses and, when challenged with EDIM no protection against infection was observed in the immunized mice. Therefore, parenteral immunization with VP6 alone elicited large anti-rotavirus IgG responses but did not elicit protection against murine rotavirus infection in this model.
Collapse
Affiliation(s)
- A H Choi
- Division of Infectious Diseases, Children's Hospital Medical Center, Cincinnati, Ohio 45229-3039, USA.
| | | | | | | |
Collapse
|
18
|
Abstract
Observations in the early 1990s that plasmid DNA could directly transfect animal cells in vivo sparked exploration of the use of DNA plasmids to induce immune responses by direct injection into animals of DNA encoding antigenic proteins. This method, termed DNA immunization, now has been used to elicit protective antibody and cell-mediated immune responses in a wide variety of preclinical animal models for viral, bacterial, and parasitic diseases. DNA vaccination is particularly useful for the induction of cytotoxic T cells. This review summarizes current knowledge on the vectors, immune responses, immunological mechanisms, safety considerations, and potential for further application of this novel method of immunization.
Collapse
MESH Headings
- Animals
- Antibodies, Antinuclear/biosynthesis
- Antibody Formation
- Antigen Presentation
- Autoimmunity
- Bacterial Infections/immunology
- Bacterial Infections/prevention & control
- Disease Models, Animal
- Genetic Vectors
- Humans
- Immune Tolerance
- Immunity, Cellular
- Immunization
- Neoplasms, Experimental/immunology
- Neoplasms, Experimental/prevention & control
- Parasitic Diseases/immunology
- Parasitic Diseases/prevention & control
- Plasmids/genetics
- Safety
- T-Lymphocytes, Cytotoxic/immunology
- T-Lymphocytes, Helper-Inducer/immunology
- Vaccines, DNA/adverse effects
- Vaccines, DNA/genetics
- Vaccines, DNA/pharmacology
- Virus Diseases/immunology
- Virus Diseases/prevention & control
Collapse
Affiliation(s)
- J J Donnelly
- Department of Virus and Cell Biology, Merck Research Laboratories, West Point, Pennsylvania 19486, USA
| | | | | | | |
Collapse
|
19
|
Abstract
Immunization with plasmid DNA encoding antigenic proteins elicits both antibody and cell-mediated immune responses. This method of producing the protein antigens of interest directly in host cells can provide appropriate tertiary structure for the induction of conformationally specific antibodies, and also facilitates the induction of cellular immune responses. DNA immunization has provided effective protective immunity in various animal models. The immune responses induced by DNA vaccines may in some instances be preferable to those produced by immunization using conventional methods. DNA vaccination appears to be applicable to a variety of pathogens and is a useful method of raising immune responses. Thus this approach to vaccination has the potential to be a successful method of rapidly screening for antigens capable of inducing protective immunity, and of inducing protective immunity against pathogens of clinical importance.
Collapse
Affiliation(s)
- J J Donnelly
- Department of Virus and Cell Biology, Merck Research Laboratories, West Point, PA 19486, USA
| | | | | |
Collapse
|